News

The company’s latest innovation provides patient self administration of drugs and biologics formulated as powders for systemic nasal, nose-to-brain, ophthalmic, sublingual and buccal routes of administration. Mystic president

In this trial, the company will evaluate the efficacy and safety of 1% LE-MPP and 0.25% LE-MPP dosed four times daily in patients having measurable intraretinal or subretinal

"The initiation of this human abuse liability study is a key milestone in the development path for CR845," said Robert Medve, M.D., Chief Medical Officer of Cara Therapeutics.

ChromaDex will provide Murdoch Childrens Research Institute with quantities of its proprietary NIAGEN™ nicotinamide riboside (NR) ingredient for research use. ChromaDex’s NIAGEN is the first and only commercially

Today’s approval follows the positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in June 2014. KALYDECO was first approved in Europe in July 2012

Developing improved biologically active molecules has benefited from the use of substituents that are chemically stable, resistant to metabolism, and combine lipophilicity with polarity to improve binding and

The interim analysis demonstrated that treatment with ofatumumab (Arzerra) met the primary endpoint of improving progression free survival (PFS). The study evaluated ofatumumab maintenance therapy versus no further

According to the company, Iluvien (190 micrograms intravitreal implant in applicator) is a sustained release intravitreal implant, which has a therapeutic effect of up to 36 months. The

The patent covers Full COLD-PCR, a foundation for the company’s highly sensitive ICE COLD-PCR technology. The COLD-PCR technology is owned by the Dana-Farber Cancer Institute, Boston USA, and